Characteristic | Erlotinib | GC | P value |
---|---|---|---|
Median age at diagnosis (years) | 60.17 ± 13.31 | 58.75 ± 12.12 | 0.71 |
Gender, n (%) | Â | Â | 0.68 |
Male | 6 (6/12, 50.00Â %) | 8 (8/12, 66.67Â %) | Â |
Female | 6 (6/12, 50.00Â %) | 4 (4/12, 33.33Â %) | Â |
Smoking duration | 6.25 ± 11.89 | 20.83 ± 21.09 | 0.10 |
Daily cigarette consumption, n | 7.92 ± 14.99 | 17.92 ± 18.27 | 0.18 |
Pathology, n (%) | Â | Â | 1.00 |
Adeno | 11 (11/12, 91.67Â %) | 11 (11/12, 91.67Â %) | Â |
LCNEC | 0 (0.00Â %) | 1 (1/12, 8.33Â %) | Â |
Adenoid cystic carcinoma | 1 (1/12, 8.33Â %) | 0 (0.00Â %) | Â |
Mutation status, n (%) | Â | Â | <0.001 |
EGFR/KRAS wild type | 0 | 11 | Â |
KRAS | 0 | 1 | Â |
Exon 19 deletion | 6 | 0 | Â |
L858R | 4 | 0 | Â |
EGFR mutation with KRAS codon | 1 | 0 | Â |
12/13* | Â | Â | Â |
EGFR mutation with EML4-ALK* | 1 | 0 | Â |
Deletion in BIM | 2/8 | 0/9 | Â |
Postoperative radiotherapy, n | 3/6 | 2/7 | 0.59 |
Median follow-up (months) | 19.3 (5.8–64.0) | 35.6 (1.7–68.7) | 0.41 |